Phase I Study of Ex Vivo Expanded/Activated Gamma Delta T-cell Infusion Following Haploidentical Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 20 Feb 2025

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs INB-100 (Primary) ; Cyclophosphamide; Fludarabine
Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Haematological malignancies; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma
Focus Adverse reactions; First in man

14 Feb 2025 According to an IN8bio media release, company expects to complete enrollment of the expansion cohort in 2025.
14 Feb 2025 Results presented in the IN8bio Media Release.
14 Feb 2025 According to an IN8bio media release, data from this study was presented at at the 2025 Transplantation & Cellular Therapy (TCT) Meetings in Hawaii.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com